Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Below are the earnings highlights for Merck & Co Inc. (MRK): Earnings: $3.743 billion in Q4 vs. -$1.226 billion in the same period ...

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a type of esophageal cancer in a late-stage trial. Merck, Eisai's ...